{"classes":[{"categories":[{"measurements":[{"comment":"Not Reached;Median was not reached due to too few PFS events.","groupId":"OG000","lowerLimit":"8.8","upperLimit":"NA","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"OS will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Everolimus and Letrozole)"}],"paramType":"MEDIAN","populationDescription":"All evaluable patients","reportingStatus":"POSTED","timeFrame":"Time from registration to death from any cause, assessed up to 2 years","title":"Overall Suravival(OS)","type":"SECONDARY","unitOfMeasure":"Months"}